GlassScriptPhysician profile
Sapna Shah
NPI 1659534543
$1,024.00
in general payments reported to CMS, 2019-2025
12 companies · $178 in 2025
The $178 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $136 · 2022: $71.99 · 2023: $282 · 2024: $356 · 2025: $178.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $771 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $771.12 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $307.88 | 2023-2025 | Farxiga, Airsupra |
| Novo Nordisk INC | $183.40 | 2023-2024 | Wegovy, Ozempic, Rybelsus |
| Xeris Pharmaceuticals, INC. | $125.23 | 2024 | Gvoke Hypopen |
| Amgen INC. | $124.70 | 2019 | |
| Sanofi-Aventis U.S. LLC | $124.57 | 2025 | |
| Becton, Dickinson and Company | $45.00 | 2024 | Bd Introsyte |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.06 | 2022 | |
| Lilly USA, LLC | $22.12 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.81 | 2022 | |
| Acadia Pharmaceuticals INC | $16.35 | 2023 | Daybue |
| Astellas Pharma US INC | $13.69 | 2025 | Veozah |
| Ivantis, INC | $11.19 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sapna Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.